Bioequivalence and Bioavailability Forum 05:08 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Narrow Therapeutic Index- valproic acid and derivatives [Regulatives / Guidelines]

posted by MaggieSantos - Portugal, 2017-04-26 18:20  - Posting: # 17271
Views: 1,818

Dear colleagues,

Concerning valproic acid and derivatives is not consentaneous that it should be considered as a narrow therapeutic índex for bioequivalence purposes. I know that for FDA it is a NTI. Do you have information for EMA, for individual European countries and for other countries around the World.

Depending on the submission country, the BE interval will differ.
Please, feel free to comment.

I need the more information I can get.

Kind Regards

MaggieSantos

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,154 posts in 4,080 threads, 1,308 registered users;
online 8 (0 registered, 8 guests [including 5 identified bots]).

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed